Press Releases

 
Press Releases
  Date Title and Summary View
May 19, 2017
CRANBURY, N.J., May 19, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics, Inc. (Nasdaq:FOLD),  has completed the analysis plan for the primary endpoints in the blinded ongoing Phase 3 clinical study (ESSENCE) of the novel topical medicine SD-101 for epidermolysis bullosa (EB). SD-101 was one of the first treatments to receive the FDA's Breakthrough T...
PDF
May 15, 2017
Mean Six-Minute Walk Distance at Month Six Improved in ERT-Naïve Patients (+52 Meters) and ERT-Switch Patients (+38 Meters) Muscle Function Improved in 9 out of 10 Patients Pulmonary Function Improved in a Majority of Patients No Infusion-Associated Reactions Following 200+ Infusions Conference Call at 8:30am ET CRANBURY, N.J., May ...
PDF
May 10, 2017
CRANBURY, N.J., May 10, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, today announced that Chip Baird, Chief Financial Officer, will present at two upcoming investor conferences: Bank of America Merrill Lynch 2017 Health Care Conference in Las Vegas, N...
PDF
May 9, 2017
100+ Fabry Disease Patients Now on Reimbursed Galafold (migalastat) in the EU On Target to Reach 300 Patients on Galafold by Year-End 2017 Additional Important Phase 1/2 Pompe Clinical Data Expected in 2Q17 and 3Q17 Phase 3 EB Topline Data on Track for 3Q17 CRANBURY, N.J., May 09, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD)...
PDF
May 2, 2017
CRANBURY, N.J., May 02, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, today announced a conference call and live audio webcast on Tuesday, May 9, 2017 at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2017. The call wil...
PDF
May 2, 2017
CRANBURY, N.J. and PARIS, May 02, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, has commenced the commercial launch of the precision medicine Galafold in France following the publication of the price in the Official Journal. Galafold is now reimbursed in Fr...
PDF
Apr 6, 2017
CRANBURY, N.J., April 06, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, is supporting several activities during Fabry Disease Awareness Month and International Pompe Day. The Fabry community has designated the month of April to honor and recognize those who...
PDF
Apr 3, 2017
Target Exceeded with More than 160 Patients Enrolled Top-Line Data on Track for 3Q17 CRANBURY, N.J., April 03, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, has completed enrollment in the ongoing Phase 3 clinical study (ESSENCE) of the ...
PDF
Mar 8, 2017
CRANBURY, N.J. and MILAN, Italy, March 08, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, has commenced the commercial launch of the precision medicine Galafold in Italy following the final publication of reimbursement guidelines by the Ministry of Health (M...
PDF
Mar 2, 2017
CRANBURY, N.J., March 02, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that management will present at two upcoming investor conferences. John Crowley, Chairman and Chief Executive Officer, will present at the Cowen & Com...
PDF
Page: FirstPrevious
2
... NextLast